Introduction
Irritable Bowel Syndrome (IBS) is a long-term digestive condition that can cause abdominal pain, bloating, diarrhoea, or constipation. For some people, these symptoms come and go and may worsen with certain foods, stress, or hormonal changes.
Medicines such as Wegovy (semaglutide) and Mounjaro (tirzepatide) are part of a class of medications called GLP-1 receptor agonists that are increasingly used to help people lose weight and manage blood sugar.
Because these medicines work by slowing digestion and altering gut motility, people with IBS often wonder whether treatment could make their symptoms better or worse.
How GLP-1 Medicines Affect the Digestive System
GLP-1 is a natural hormone that helps your body regulate appetite, digestion, and blood sugar. When taken as an injection, GLP-1 medicines:
- Slow the emptying of the stomach, helping you feel full for longer.
- Reduce appetite, leading to smaller portion sizes.
- Influence gut motility, which can affect bowel movement patterns.
For most people, these effects support weight loss and help stabilise blood sugar. However, if you have IBS, these same changes may temporarily alter your digestion leading to bloating, nausea, constipation, or loose stools, particularly in the early stages of treatment (1-3).
What the Evidence Says
Research on GLP-1 medicines in people with IBS is still emerging. Studies show that these medicines can influence the enteric nervous system, sometimes improving symptoms of constipation-predominant IBS, but potentially worsening diarrhoea-predominant IBS during dose adjustments (3-5).
Some experimental data suggest GLP-1 analogues may help reduce gut hypersensitivity and pain signalling, meaning they could even have protective effects in certain IBS subtypes (6).
Overall, the impact varies between individuals and careful dose titration can make a big difference.
What Patients Should Consider
1.Before Starting Treatment
- Discuss your IBS pattern (constipation, diarrhoea, or mixed) with your prescriber before starting GLP-1 treatment.
If you regularly use medicines such as laxatives, peppermint oil, or antispasmodics, let your pharmacist or doctor know, as these may need adjusting.
2.During Treatment / Maintenance
- Monitor your bowel pattern: keep a simple diary of stool frequency, consistency, and bloating.
- Increase fibre slowly and drink plenty of water as dehydration can worsen constipation.
- If you experience nausea, reflux, or abdominal discomfort, try smaller, more frequent meals.
- For diarrhoea-dominant IBS, avoid caffeine, alcohol, and high-fat meals around injection days.
- Speak to your prescriber if your symptoms become persistent or affect your daily life.
3. When to Seek Medical Advice
- If you experience severe or persistent abdominal pain, bloating, or vomiting (possible pancreatitis or bowel obstruction).
- If constipation lasts more than 5–7 days despite laxatives or hydration.
- If you develop blood in the stool or unexplained weight loss unrelated to treatment.
If IBS symptoms suddenly change or worsen significantly after starting GLP-1 therapy.
For severe pain, dehydration, or vomiting, call 111 or attend A&E.
Lifestyle Tips for Managing IBS on GLP-1 Treatment
- Eat slowly and chew food thoroughly to aid digestion.
- Avoid trigger foods that worsen your IBS (often caffeine, spicy foods, or high-fat meals).
- Stay hydrated, especially during the first few weeks of treatment.
- Include soluble fibre sources (e.g., oats, flaxseed, or psyllium husk).
- Exercise regularly to help stimulate gut movement and relieve stress.
- Practice relaxation techniques such as deep breathing or yoga — stress strongly affects IBS symptoms.
Summary
GLP-1 medicines like Wegovy and Mounjaro can safely be used by people with IBS, but some may notice temporary digestive changes such as bloating, constipation, or diarrhoea during dose adjustment.
With careful monitoring, dietary awareness, and good hydration, most patients find their symptoms settle over time. Always discuss your bowel health with your prescriber before starting treatment so your plan can be tailored to you.
References
- Nauck MA, Meier JJ. Glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art. Lancet Diabetes Endocrinol. 2021;9(12):865–76.
- Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989–1002.
- Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab. 2022;35(1):1–23.
- Gribsholt SB, Ravn P, et al. Gastrointestinal tolerability of GLP-1 receptor agonists: insights from clinical trials. Diabetes Obes Metab. 2023;25(3):761–73.
- Halland M, et al. The role of GLP-1 in gastrointestinal motility and functional bowel disorders. Neurogastroenterol Motil. 2020;32(6):e13885.
- Egecioglu E, et al. GLP-1 analogues and gut sensory function: potential relevance for irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol. 2018;315(3):G431–G440.